Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Clears For Market World's First H1N1 Flu Vaccine, By Sinovac

This article was originally published in PharmAsia News

Executive Summary

China has given its clearance to the first locally mass-produced H1N1 flu vaccine to Sinovac Biotech. The final approval came after a panel of experts earlier in the week recommended both Sinovac and Hualan Biological Engineering be allowed to produce their versions. As the first, Sinovac's one-shot treatment is likely to be the first on the market, contributing enough dosages to treat 5 percent of the Chinese population by the end of the year. Sinovac was the first company globally to complete clinical trials on a vaccine. (Click here for more

You may also be interested in...

EU Unveils Ambitions To ‘Future-Proof’ Entire Drug Regulatory Framework

Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.

AdvaMed Throws Weight Behind Protestors In Ongoing US Demonstrations

AdvaMed CEO Scott Whitaker shared a letter he sent to member companies voicing support for the ongoing protests around the US against police brutality that were sparked after the killing of George Floyd. “While we continue our single-minded pursuit of medical breakthroughs to treat and cure disease, we must also have a single-minded focus on eradicating the disease of racism in this country and around the world,” Whitaker wrote.

FDA To Periodically Publish List Of NOAs Due To COVID-19, But No Impact On EUA Sponsors

Due to strained resources and the slew of emergency use authorizations being requested by sponsors because of the COVID-19 crisis, the agency will now periodically publish Notices of Availabilities in the Federal Register instead of publishing immediately as the EUAs are handed out. However, companies will still get their NOA letters and can start marketing their products, and the agency will post the announcements sooner on its website.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts